Cell death biotech Kojin winds down, citing 4 funding challenges


cafead

Administrator
Staff member
  • cafead   Feb 16, 2025 at 07:52: PM
via Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.

The cancer- and autoimmune-focused company will wind down operations over the next few months, according to a LinkedIn status from the business posted on Feb. 13. The biotech had hoped to use iron-dependent cell death, also known as ferroptosis, to treat drug-resistant cancer and other conditions.

article source
 



Write your reply...